Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gaurav Malhotra

Internal Medicine Spring Hill, FL Medical Doctor

NPI 1679641039 CMS profile 167037

3378 Mariner Blvd, Spring Hill, FL 34609

Open in the dashboard

General payments

$3,539

98 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$64,676 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Gaurav Malhotra of Spring Hill, FL is reported in the CMS Open Payments database as having received $3,539 across 98 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $64,676 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2024 General $51 3
2023 General $181 9
2022 General $2,133 22
2021 General $435 27
2020 General $193 8
2019 General $528 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gaurav Malhotra
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gaurav Malhotra were reported at $18. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gaurav Malhotra Internal Medicine median Middle half National median
2019 $528 $159 $48–$570 $163
2020 $193 $119 $33–$402 $114
2021 $435 $135 $37–$521 $132
2022 $2,133 $141 $42–$496 $149
2023 $181 $149 $45–$519 $160
2024 $51 $154 $47–$537 $164
2025 $18 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Research & Development, LLC $1,965 13 payments
  2. GlaxoSmithKline, LLC. $399 23 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $227 14 payments
  4. Amarin Pharma Inc. $132 4 payments
  5. AstraZeneca Pharmaceuticals LP $115 1 payment
  6. Novartis Pharmaceuticals Corporation $104 6 payments
  7. Pfizer Inc. $84 5 payments
  8. AbbVie, Inc. $65 3 payments
  9. Amgen Inc. $43 3 payments
  10. Xeris Pharmaceuticals, Inc. $38 2 payments
  11. Other $367 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,194 93 payments
  2. Travel and Lodging $1,345 5 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $315 17 payments
  2. SPIRIVA RESPIMAT $152 8 payments
  3. FASENRA $115 1 payment
  4. ENTRESTO $104 6 payments
  5. STIOLTO RESPIMAT Respiratory $100 5 payments
  6. Vascepa $100 2 payments
  7. ELIQUIS $70 4 payments
  8. LEQVIO $65 4 payments
  9. JARDIANCE $59 5 payments
  10. STIOLTO RESPIMAT Respiratory $52 3 payments
  11. Other $939 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

8,625

Median for Internal Medicine: 777

Drug cost

$298,264

Median for Internal Medicine: $73,373

Branded share of claims

13.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 58 $62,333
Ozempic Semaglutide Brand 39 $52,227
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 30 $25,726
Xarelto Rivaroxaban Brand 11 $16,551
Rosuvastatin Calcium Generic 1,130 $10,930
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 27 $8,185
Novolin 70-30 Insulin Nph Hum/Reg Insulin Hm Brand 26 $7,248
Novolin 70-30 Flexpen Insulin Nph Hum/Reg Insulin Hm Brand 37 $6,602
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 29 $6,301
Albuterol Sulfate Hfa Albuterol Sulfate Brand 193 $5,981

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$81,361

Medicare's payments for the services billed

Medicare patients

228

Average age 72

Services billed

1,234

131 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Chronic kidney disease 36%
Ischemic heart disease 32%
Depression 30%
COPD 29%
Diabetes 26%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $19
$19 30 —
ELIQUIS
  • PFIZER INC. $5
$5 58 —
NURTEC ODT
  • PFIZER INC. $5
$5 — —
PAXLOVID
  • PFIZER INC. $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record